Omada Health (NASDAQ:OMDA) President Sells 8,866 Shares

by · The Cerbat Gem

Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) President Wei-Li Shao sold 8,866 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.02, for a total transaction of $221,827.32. Following the sale, the president directly owned 307,372 shares in the company, valued at $7,690,447.44. The trade was a 2.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Wei-Li Shao also recently made the following trade(s):

  • On Friday, June 12th, Wei-Li Shao sold 4,589 shares of Omada Health stock. The shares were sold at an average price of $17.24, for a total transaction of $79,114.36.

Omada Health Stock Performance

Shares of OMDA traded down $0.17 during trading hours on Wednesday, hitting $23.84. The stock had a trading volume of 1,552,408 shares, compared to its average volume of 1,274,695. The firm has a 50-day moving average price of $20.61 and a 200 day moving average price of $16.32. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 476.80 and a beta of 1.73.

Omada Health (NASDAQ:OMDA – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. The company had revenue of $87.83 million for the quarter, compared to analyst estimates of $80.93 million. As a group, analysts predict that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Omada Health

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in shares of Omada Health in the second quarter worth about $32,000. Bellevue Group AG lifted its position in Omada Health by 0.7% during the third quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock worth $5,567,000 after buying an additional 1,791 shares in the last quarter. Quarry LP acquired a new position in Omada Health during the fourth quarter worth $29,000. Barclays PLC grew its holdings in Omada Health by 14.6% in the 4th quarter. Barclays PLC now owns 14,850 shares of the company’s stock valued at $234,000 after buying an additional 1,888 shares in the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in Omada Health in the 4th quarter valued at $32,000.

Omada Health News Roundup

Here are the key news stories impacting Omada Health this week:

  • Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
  • Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
  • Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
  • Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
  • Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
  • Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

Wall Street Analysts Forecast Growth

OMDA has been the subject of several recent analyst reports. Morgan Stanley restated an “overweight” rating and issued a $30.00 price target on shares of Omada Health in a research note on Monday, June 22nd. BMO Capital Markets reiterated an “outperform” rating and set a $24.00 price target on shares of Omada Health in a research report on Friday, August 7th. Wells Fargo & Company raised their price objective on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Omada Health in a research note on Friday, May 8th. Finally, Evercore reiterated an “outperform” rating and set a $20.00 target price on shares of Omada Health in a research report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.75.

View Our Latest Report on Omada Health

About Omada Health

(Get Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

Read More